Intravenous ferric derisomaltose for patients with heart failure: does iron heart translate into IRONMAN?
- PMID: 36786662
- DOI: 10.1093/eurheartj/ehad076
Intravenous ferric derisomaltose for patients with heart failure: does iron heart translate into IRONMAN?
Conflict of interest statement
Conflicts of interest R.V. received speaker’s fees from Abbott Vascular, Amgen, and Terumo, outside the submitted work. D.P. received speaker’s fees from Daiichi-Sankyo, outside the submitted work.
Comment on
-
Intravenous ferric derisomaltose in patients with heart failure and iron deficiency in the UK (IRONMAN): an investigator-initiated, prospective, randomised, open-label, blinded-endpoint trial.Lancet. 2022 Dec 17;400(10369):2199-2209. doi: 10.1016/S0140-6736(22)02083-9. Epub 2022 Nov 5. Lancet. 2022. PMID: 36347265 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
